Nodule at injection site as an adverse event following immunization: Case definition and guidelines for data collection, analysis, and presentation

Vaccine

Volumn 22, Issue 5-6, 2004, Pages 575-585

  Rothstein, Edward ^a   Kohl, Katrin S ^b   Ball, Leslie ^c   Halperin, Scott A ^d   Halsey, Neal ^e   Hammer, Sandra Jo ^f   Heath, Paul T ^g   Hennig, Renald ^h   Kleppinger, Cynthia ^c   Labadie, Jerry ⁱ   Varricchio, Frederick ^c   Vermeer, Patricia ^j   Walop, Wikke ^k  

^a Pennridge Pediatric Associates   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d DALHOUSIE UNIVERSITY   (Canada)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h Chiron Behring GmbH & Co   (Germany)

ⁱ Netherlands Pharmacovigilance Centre   (Netherlands)

^j NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^k HEALTH CANADA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; LIVE VACCINE; TUMOR VACCINE;

CLINICAL FEATURE; CONCEPT FORMATION; DATA ANALYSIS; FOLLOW UP; GRANULOMA; HEALTH STATUS; HUMAN; IMMUNIZATION; INFORMATION PROCESSING; INJECTION SITE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN NODULE; SYMPTOM; TIME; VACCINATION REACTION;

EID: 9144239218     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.09.005     Document Type: Article

References (44)

1. Erdohazi M., Newman R.L. Aluminum hydroxide granuloma. Br. Med. J. 3:1971;621-623.
2. Fawcett H.A., Smith N.P. Injection site granuloma due to aluminum. Arch. Dermatol. 120:1984;1318-1322.
3. Stringfellow H.F., Howat A.J. Postimmunization (vaccination) injection-site reactions. Am. J. Surg. Pathol. 18:1994;1179-1180.
4. Miliauskas J.R., Mukherjee T., Dixon B. Postimmunization (vaccination) injection-site reactions: a report of four cases and review of the literature. Am. J. Surg. Pathol. 17:1993;516-524.
5. Slater D.N., Underwood J.C., Durrant T.E., Gray T., Hopper I.P. Aluminum hydroxide granulomas: light and electron microscopic studies and X-ray microanalysis. Br. J. Dermatol. 107:1982;103-108.
6. Cosnes A., Flechet M.L., Revuz J. Inflammatory nodular reactions after hepatitis B vaccination due to aluminum sensitization. Contact Dermatol. 23:1990;65-67.
7. Wahl M., Hermodsson S. Intradermal. Scand. J. Infect. Dis. 19:1987;617-621.
8. Eickhoff T.C., Myers M. Workshop summary: aluminum in vaccines. Vaccine. 20(Suppl):2002;S1-S4.
9. Baylor N.W., Egan W., Richman P. Aluminum salts in vaccines - US perspective. Vaccine. 20(Suppl):2002;S18-S23.
10. Fiejka M., Aleksandrowicz J. Aluminum as an adjuvant in vaccines and post-vaccine reactions. Rocz. Panstw. Zakl. Hig. 44:1993;73-80.
11. Pittman P.R. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine. 20(Suppl):2002;S48-S50.
12. Araujo O.O., Neto E.F., Vespa G.N.R.et al. Associated or combined vaccination of Brazilian infants with a conjugate Haemophilus influenzae type B (Hib) vaccine. Vaccine. 19:2001;367-375.
13. Bernstein H.H., Rothstein E.P., Pichichero M.E.et al. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children. AJDC. 146:1992;556.
14. Blennow M., Granstrom M., Strandell A.et al. Adverse reactions after diphtheria-tetanus booster in 10-year-old schoolchildren in relation to the type of vaccine given for the primary vaccination. Vaccine. 12:1994;427-430.
15. Castillo de Febres O., Chacon de Petrola M., Casanova de Escalona L.et al. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4-15 year old children. Vaccine. 18:2000;656-664.
16. Dagan R., Greenberg D., Gehtman P.G. Safety and immunogenicity of a new formulation on an inactivated hepatitis A vaccine. Vaccine. 17:1999;1919-1925.
17. Decker M.D., Edwards K.M., Steinhoff M.C.et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 96(Suppl):1995;557-566.
18. Edwards K.M., Decker M.D., Graham B.S.et al. Adult immunization with acellular pertussis vaccine. JAMA. 269:1993;53-56.
19. Falvo C., Horowitz H. Adverse reactions associated with simultaneous administration of multiple vaccines to travelers. J. Gen. Intern. Med. 9:1994;255-260.
20. Herrington D.A., Losonsky G.A., Smith G.et al. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malariae vaccine produced in Lepidopteran cells. Vaccine. 10:1992;841-846.
21. Jackson L.A., Benson P., Sneller V.P.et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 281:1999;243-248.
22. Keitel W., Couch R., Bond N.et al. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine. 11:1993;909-913.
23. Keitel W.A., Muenz L.R. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J. Infect. Dis. 180:1999;397-403.
24. Keller D., Koster F.T., Marks D.H.et al. Safety and immunogenicity of a recombinant outer surface protein A lyme vaccine. JAMA. 271:1994;1764-1768.
25. Lee H.J., Kang J.H., Henrichsen J.et al. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy children and in children at increased risk of pneumococcal infection. Vaccine. 13:1995;1533-1538.
26. Lina B., Fletcher M.A., Valette M. A TritonX-100-split virion influenza vaccine is safe and fulfills the Committee for Proprietary Medicinal Products (CPMP) recommendations for the European Community for immunogenicity, in children, adults and the elderly. Biologicals. 28:2000;95-103.
27. Lopez E.L., Xifro M.D.C., Torrado L.E.et al. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr. Infect. Dis. J. 20:2001;48-52.
28. Mark A., Carlsson R.M., Granstrom M.et al. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine. 17:1999;2067-2072.
29. Nichol K.L., Margolis K.L., Lind A.et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch. Intern. Med. 156:1996;1546-1550.
30. Odelram H., Granstrom M., Hedenskog S., Duchen K., Bjorksten B. Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions, and aluminium content of the vaccines. Pediatr. Allergy Immun. 5:1994;118.
31. Pichichero M.E., Edwards K.M., Anderson E.L.et al. Safety and immunogenicity of an acellular-pertussis vaccine booster in 15-20 month old children previously immunized with acellular or whole-cell pertussis vaccine as infants. Pediatrics. 91:1993;756.
32. Rothstein EP. Safety of a 5th dose of a diphtheria-tetanus-acellular pertussis vaccine (Tripedia) [Abstract]. San Francisco, CA: American Pediatric Society, Society for Pediatric Research; 1-4 May 1999.
33. Rothstein E.P., Anderson E.L., Decker M.D.et al. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Vaccine. 17:1999;2999.
34. Schmitt HJ, Mohnike K, Zepp F, Herden P. Reactogenicity and safety of the Biken acellular pertussis vaccine in 497 adults [Abstract #86G.G-30]. In: Proceedings of the 38th Interscience Conference on Antimicrobial Agents (ICAAC), San Diego; September 1998. p. 292.
35. Butler N.R., Voyce M.A., Burland W.L., Hilton M.L. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccine for the immunization of infants. Br. Med. J. 1:1969;663-666.
36. Bernier R.H., Frank J.A., Nolan T.F. Abscesses complicating DTP vaccination. Am. J. Dis. Child. 135:1981;826.
37. Feijka M., Aleksandrowicz J. Aluminum as an adjuvant and post-vaccine reactions. Rocz Panstw hig. 44:1993;73-80.
38. Bordet A.L., Michenet P., Cohen C.et al. Post-vaccination granuloma due to aluminium hydroxide. Ann. Pathol. 21:2001;149-152.
39. Cominos D., Strutton G., Busmanis I. Granulomas associated with tetanus toxoid immunization. Am. J. Dermatopathol. 15:1993;114-117.
40. Bordet A.L., Michenet P., Cohen C.et al. Post-vaccination granuloma due to aluminium hydroxide. Ann. Pathol. 21:2001;149-152.
41. Culora G.A., Ramsay A.D., Theaker J.M. Aluminium and injection site reactions. J. Clin. Pathol. 49:1996;844-847.
42. Kaaber K., Nielsen A.O., Veien N.K. Vaccination granulomas and aluminium allergy: course and prognostic factors. Contact Dermat. 26:1992;304-306.
43. Lami G., Kardevan A., Ivanyi T.S., Gonye S., Tuboly S. Settlement of mycobacteria in aluminium hydroxide-induced cutaneous granuloma of cattle. Acta Vet. Acad. Ungaricae. 20:1970;91-102.
44. The CONSORT statement and MOOSE, available at: http://www.consort- statement.org/ .